Cue Biopharma (CUE) Q2 2026 earnings summary

Executive summary

• Entered exclusive license agreement with Ascendant Health Sciences for CUE-221, a novel anti-IgE antibody, with a $15M upfront payment and up to $676.5M in milestones and royalties.

• Completed a $27.6M private placement in May 2026 and a $49.8M private placement in July 2026 to strengthen liquidity.

• Appointed a new President and CEO, Shao-Lee Lin, with a new executive employment agreement.

Financial highlights

• Collaboration revenue for Q2 2026 was $7.9M, up from $3.0M in Q2 2025, driven by BI milestone payments.

• Net loss for Q2 2026 was $153.1M, compared to $8.5M in Q2 2025, primarily due to one-time non-cash charges related to warrant issuances and the Ascendant license.

• Cash and cash equivalents as of June 30, 2026, were $17.4M, with an additional $49.8M received in July 2026.

Outlook and guidance

• Cash runway expected to last at least twelve months from the financial statement issuance date, supported by recent financings.

• Plans to initiate a global Phase 2b trial for CUE-221 in food allergy after reviewing Phase 2 data from China.

• IND submission for CUE-401 expected by end of 2026, with Phase 1 trial initiation planned.